BIRC5 and non-small cell lung carcinoma: The releasing of functional siRNA from our RNA nanoparticles was documented by animal trials in multiple publications showing the inhibition of tumors in non-small-cell lung (NSCLC),81 triple negative breast (TNBC),30 and prostate30 cancer models when Survivin siRNA was fused onto RNA nanoparticles and delivered to tumors (Figure 5).